RxDoctor Payments Data

Gene Bigham, MD

Internal Medicine · Desoto, TXNPI 1538126719

Payments from drug & device makers

$833in general payments, 2019–2025

Across 49 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$194
  • Pfizer$86
  • Teva Pharmaceuticals USA, Inc.$86
  • Sunovion Pharmaceuticals Inc.$52
  • Novartis$51
  • Eisai Inc.$50
  • plus $314 from 14 others

What the payments were for

  • Food & beverage$833100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$833 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$153,359
Medicare patients
399
Services billed
2,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban462$167,667
OzempicSemaglutide73$97,784
TrulicityDulaglutide94$95,777
IngrezzaValbenazine Tosylate25$93,149
XareltoRivaroxaban152$70,221
RexultiBrexpiprazole87$61,667
JanuviaSitagliptin Phosphate139$47,532
JardianceEmpagliflozin64$40,309
GemtesaVibegron152$39,395
Divalproex Sodium537$37,524
EntrestoSacubitril/Valsartan65$25,922
MounjaroTirzepatide23$25,024
FarxigaDapagliflozin Propanediol27$23,451
Atorvastatin Calcium1,560$21,353
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog98$19,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$86$167,667462 claims
Lilly USA, LLCTrulicity, Mounjaro$30$120,801117 claims
Novo NordiskOzempic$194$97,78473 claims
Neurocrine Biosciences, Inc.Ingrezza$23$93,14925 claims
Johnson & JohnsonXarelto, Prezcobix$22$87,615164 claims
Otsuka America Pharmaceutical, Inc.Rexulti$21$61,66787 claims
Sumitomo Pharma America, Inc.Gemtesa$12$39,395152 claims
AbbVieLinzess, Qulipta, Creon$26$27,26844 claims
NovartisEntresto$51$25,92265 claims
AstraZenecaFarxiga$12$23,45127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Desoto

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →